Impax Asset Management Group’s Bristol-Myers Squibb BMY Stock Holding History

Impax Asset Management Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.84M	Sell	101,377 -2,350	-2%	-$135K	0.04%	214
2026 Q1	$6.29M	Sell	103,727 -40,950	-28%	-$2.39M	0.04%	189
2025 Q4	$7.8M	Sell	144,677 -3,367	-2%	-$162K	0.05%	173
2025 Q3	$6.68M	Sell	148,044 -4,251	-3%	-$199K	0.04%	173
2025 Q2	$7.05M	Buy	152,295 +20,864	+16%	+$1.02M	0.04%	173
2025 Q1	$8.02M	Sell	131,431 -16,815	-11%	-$980K	0.05%	156
2024 Q4	$8.38M	Sell	148,246 -100,826	-40%	-$5.63M	0.04%	174
2024 Q3	$12.9M	Sell	249,072 -2,574	-1%	-$121K	0.05%	143
2024 Q2	$10.5M	Sell	251,646 -996	-0.4%	-$44.6K	0.04%	158
2024 Q1	$13.7M	Buy	252,642 +66,792	+36%	+$3.4M	0.05%	145
2023 Q4	$9.54M	Sell	185,850 -92,216	-33%	-$4.84M	0.04%	179
2023 Q3	$16.1M	Sell	278,066 -7,511	-3%	-$460K	0.07%	128
2023 Q2	$18.3M	Sell	285,577 -402,674	-59%	-$27M	0.07%	128
2023 Q1	$47.7M	Buy	688,251 +36,679	+6%	+$2.59M	0.2%	104
2022 Q4	$46.9M	Buy	651,572 +127,114	+24%	+$9.58M	0.21%	101
2022 Q3	$37.3M	Buy	524,458 +156,789	+43%	+$11.4M	0.19%	98
2022 Q2	$28.3M	Sell	367,669 -263,726	-42%	-$20.1M	0.14%	106
2022 Q1	$46.1M	Sell	631,395 -78,223	-11%	-$5.25M	0.19%	92
2021 Q4	$44.2M	Buy	709,618 +65,395	+10%	+$3.84M	0.16%	94
2021 Q3	$38.1M	Buy	644,223 +80,722	+14%	+$5.32M	0.16%	97
2021 Q2	$37.7M	Hold	563,501	–	–	0.17%	92
2021 Q1	$35.6M	Buy	563,501 +152,621	+37%	+$9.5M	0.18%	82
2020 Q4	$25.5M	Hold	410,880	–	–	0.16%	85
2020 Q3	$24.8M	Buy	410,880 +60,000	+17%	+$3.61M	0.22%	78
2020 Q2	$20.6M	Hold	350,880	–	–	0.21%	79
2020 Q1	$19.6M	Buy	350,880 +62,800	+22%	+$3.84M	0.26%	78
2019 Q4	$18.5M	Buy	288,080 +12,868	+5%	+$737K	0.21%	87
2019 Q3	$14M	Hold	275,212	–	–	0.18%	93
2019 Q2	$12.5M	Buy	275,212 +83,200	+43%	+$3.88M	0.16%	98
2019 Q1	$9.16M	Buy	+192,012	New	+$9.56M	0.13%	121

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Impax Asset Management Group's BMY Position: Q2 2026 in Review

Impax Asset Management Group reduced its Bristol-Myers Squibb (BMY) stake by 2.3% in Q2 2026, selling an estimated $135K and leaving 101,377 shares worth $5.84M. The position accounts for 0.04% of the portfolio, ranked #214.

Impax Asset Management Group first reported a position in BMY in Q1 2019 and has held it in 30 quarters since. The position peaked at $47.7M in Q1 2023. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Impax Asset Management Group held 101,377 shares of Bristol-Myers Squibb worth $5.84M as of Q2 2026.
Impax Asset Management Group sold 2,350 Bristol-Myers Squibb shares in Q2 2026, an estimated $135K.
Bristol-Myers Squibb made up 0.04% of Impax Asset Management Group's portfolio in Q2 2026, its #214 holding.
Impax Asset Management Group first reported a position in Bristol-Myers Squibb in Q1 2019 and has held it in 30 quarters since.
Impax Asset Management Group's Bristol-Myers Squibb position peaked at $47.7M in Q1 2023.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Impax Asset Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.